Longeveron Expands Executive Leadership Team; Appoints K. Chris Min, M.D., Ph.D. as Chief Medical Officer
05 April 2022 - 10:00PM
Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a
clinical stage biotechnology company developing cellular therapies
for chronic, aging-related and other specific life-threatening
conditions, announced today the addition of K. Chris Min, M.D.,
Ph.D. to the Longeveron executive leadership team in the role of
Chief Medical Officer (CMO), effective April 4, 2022. Dr. Min will
lead global clinical development and regulatory strategy for
Longeveron’s investigational products, with advancing its lead
product Lomecel-B into pivotal stage trials and approval as his top
priority.
“We are very pleased to welcome Chris to the
Longeveron team,” said CEO Geoff Green. “The depth and breadth of
both his medical and industry experience will be invaluable as we
move through multiple Phase 2 clinical trials of Lomecel-B. As a
board-certified neurologist with deep clinical experience, Chris
will be instrumental in guiding our Alzheimer’s development
program. In addition, his regulatory and regenerative medicine
experience will be a tremendous benefit to our Aging Frailty and
rare pediatric Hypoplastic Left Heart Syndrome (HLHS)
programs.”
Dr. Min brings to Longeveron over a decade of
pharma and biotech clinical development experience. This includes
work on novel cell therapy, leading R&D and clinical teams, and
advancing regulatory engagements with the U.S. Food and Drug
Administration (FDA) from early clinical stage Investigational New
Drug (IND) applications through to pre-approval New Drug
Applications (NDA).
“I couldn’t be more excited to join the
Longeveron team at this precise moment along Lomecel-B’s
development path,” said Dr. Min. “With clinical efficacy trials in
Alzheimer’s and Hypoplastic Left Heart Syndrome (HLHS) underway,
and the Aging Frailty program positioned to expand into Phase 2
trials in Asia, I anticipate ample opportunity to explore the
therapeutic potential of Lomecel-B across a variety of
life-threatening conditions with high unmet needs.”
Most recently, Dr. Min served as Vice President
and Head of Medical & Clinical Development at Enterin Inc.
Prior to his role at Enterin, Dr. Min was the Head of Clinical
Pharmacology at Cerevel Therapeutics, leading a broad portfolio of
neuroscience-focused therapeutics and spearheading a successful IND
submission for CVL-936, an investigational therapy for the
treatment of substance use disorder.
Before joining Enterin, Dr. Min was the Senior
Medical Director of Neurology at BlueRock Therapeutics where he
championed the clinical development process for pluripotent stem
cell-derived dopaminergic neurons to treat Parkinson’s Disease. Dr.
Min began his industry career at Merck Research Laboratories, where
he played a leadership role on teams ranging from early-stage
discovery to late-stage clinical development. At Merck, Dr. Min
served as clinical team lead for more than ten Phase 1 clinical
studies, including a pivotal Phase 1 safety study that led to the
US approval in 2015 for Bridion®, a drug indicated for the reversal
of neuromuscular blockade induced by rocuronium or vecuronium,
typically during surgery. Bridion® was the first novel anesthesia
product in over two decades.
Prior to his industry experience, Dr. Min served
as a research clinician, faculty member, and attending physician at
Columbia University Irving Medical Center and Harlem Hospital. Dr.
Min earned an M.D. from the Weill Medical College of Cornell
University, a Ph.D. in Biochemistry from The Rockefeller University
and a B.A. in Biochemical Sciences from Harvard University.
About Longeveron Inc.Longeveron
is a clinical stage biotechnology company developing cellular
therapies for specific aging-related and life-threatening
conditions. The Company’s lead investigational product is the
LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is
derived from culture-expanded medicinal signaling cells (MSCs) that
are sourced from bone marrow of young, healthy adult donors.
Longeveron believes that by using the same cells that promote
tissue repair, organ maintenance, and immune system function, it
can develop safe and effective therapies for some of the most
difficult disorders associated with the aging process and other
medical disorders. Longeveron is currently sponsoring Phase 1 and 2
clinical trials in the following indications: Aging Frailty,
Alzheimer’s disease, the Metabolic Syndrome, Acute Respiratory
Distress Syndrome (ARDS), and hypoplastic left heart syndrome
(HLHS). The Company’s mission is to advance Lomecel-B and other
cell-based product candidates into pivotal Phase 3 trials, with the
goal of achieving regulatory approvals, subsequent
commercialization, and broad use by the healthcare community.
Additional information about the Company is available at
www.longeveron.com.
Contact:Brendan PayneStern
Investor RelationsTel: (212) 362-1200Email:
Brendan.payne@sternir.com
Source: Longeveron
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jun 2024 to Jul 2024
Longeveron (NASDAQ:LGVN)
Historical Stock Chart
From Jul 2023 to Jul 2024